I. Krämer

发表

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

D. Hose, H. Goldschmidt, A. Ho, 2016, Oncoimmunology.

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

A. Ho, A. Benner, Maral Saadati, 2017, BMC Cancer.

The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma

K. Herfarth, A. Ho, M. Witzens‐Harig, 2015, Annals of Hematology.

Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era

A. Ho, M. Witzens‐Harig, N. Lehners, 2016, Leukemia & lymphoma.

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

S. Dietrich, P. Dreger, H. Kräusslich, 2021, Blood.

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.

N. Schmitz, H. Döhner, M. Hallek, 2017, Blood.

Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

A. Ho, A. Benner, Maral Saadati, 2017, BMC Cancer.

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

N. Schmitz, H. Döhner, M. Hallek, 2016 .